Three-dimensional culture system identifies a new mode of cetuximab resistance and disease-relevant genes in colorectal cancer
Open accessThe DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
Abstract
Significance: By culturing a human colorectal cancer (CRC) cell line (HCA-7) in 3D, we have generated two cell lines (CC and SC) with distinct morphological, genetic, biochemical, and functional properties. Using this 3D system, we have discovered that increased tyrosine phosphorylation of MET and RON results in cetuximab resistance in the SC cell line that can be overcome by addition of the dual MET/RON tyrosine kinase inhibitor, crizotinib. We have also identified that increased epithelial, but not stromal, versican staining correlates with reduced survival in a clinically annotated CRC tissue microarray.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“We have recently identified novel modes of cetuximab-resistance, including both genetic [46] and non-genetic alterations, for instance changes in long non-coding RNA (lncRNA), that are present in both intrinsic and acquired resistance [47].”
From Combined blockade of EGFR and glutamine metabolism in preclinical models of colorectal cancer (2020) · cites this paper as [46]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“3D cell culture systems have been demonstrated to more closely mimic in vivo behavior than 2D cultures [46].”
From Combined blockade of EGFR and glutamine metabolism in preclinical models of colorectal cancer (2020) · cites this paper as [46]
The cited source says what the claim attributes to it.
In the citing paper
“a cell line that our group has previously shown to be intrinsically cetuximab-resistant in 3D cultures, HCA-7 SC [46]”
From Combined blockade of EGFR and glutamine metabolism in preclinical models of colorectal cancer (2020) · cites this paper as [46]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482 · cited 1×
“Benjamini and Hochberg’s multiple test (63).”
Chromatin modifications and their function
Kouzarides, T. (2007) · Cell · doi:10.1016/j.cell.2007.02.005 · Cited by 10,883
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496 · cited 1×
“Although MET amplification has been reported as a mechanism of acquired resistance to EGFR inhibition (34, 35), increased tyrosine phosphorylation of MET (independent of its amplification) has not.”
BackgroundAnaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
Kwak, E. L., Bang, Y.-J., Camidge, D. R., Shaw, A. T., Solomon, B., Maki, R. G., Ou, S.-H. I., Dezube, B. J., Jänne, P. A., Costa, D. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1006448 · Cited by 4,446 · cited 1×
“Crizotinib is a broadly acting, small-molecule tyrosine kinase inhibitor that is approved for clinical use for individuals with non–small-cell lung carcinoma (36).”
BackgroundMutations of bacteria from virus sensitivity to virus resistance
Luria, S. E., & Delbrück, M. (1943) · Genetics · doi:10.1093/genetics/28.6.491 · Cited by 3,894
Crizotinib versus Chemotherapy in Advanced ALK -Positive Lung Cancer
Shaw, A. T., Kim, D.-W., Nakagawa, K., Seto, T., Crinó, L., Ahn, M.-J., De Pas, T., Besse, B., Solomon, B. J., Blackhall, F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1214886 · Cited by 3,381
Oshima, M., Dinchuk, J. E., Kargman, S. L., Oshima, H., Hancock, B., Kwong, E., Trzaskos, J. M., Evans, J. F., & Taketo, M. M. (1996) · Cell · doi:10.1016/s0092-8674(00)81988-1 · Cited by 2,366
Irizarry, R. A., Ladd-Acosta, C., Wen, B., Wu, Z., Montano, C., Onyango, P., Cui, H., Gabo, K., Rongione, M., Webster, M., et al. (2009) · Nature Genetics · doi:10.1038/ng.298 · Cited by 2,177 · cited 1×
“These domains are known to acquire DNA hypomethylation early in CRC progression compared with normal tissue, and it is thought that loss of DNA methylation in these regions might confer regulatory plasticity to these domains through dynamic regulation of chromatin modifications (27, 28).”
Backgroundlumi: a pipeline for processing Illumina microarray
Du, P., Kibbe, W. A., & Lin, S. M. (2008) · Bioinformatics · doi:10.1093/bioinformatics/btn224 · Cited by 2,019
Debnath, J., Muthuswamy, S. K., & Brugge, J. S. (2003) · Methods · doi:10.1016/s1046-2023(03)00032-x · Cited by 1,995
Cited by
Lu, Y., Zhao, X., Liu, Q., Li, C., Graves-Deal, R., Cao, Z., Singh, B., Franklin, J. L., Wang, J., Hu, H., et al. (2017) · Nature Medicine · doi:10.1038/nm.4424 · Cited by 425
Self-citationZhang, Q., Jeppesen, D. K., Higginbotham, J. N., Graves-Deal, R., Trinh, V. Q., Ramirez, M. A., Sohn, Y., Neininger, A. C., Taneja, N., McKinley, E. T., et al. (2021) · Nature Cell Biology · doi:10.1038/s41556-021-00805-8 · Cited by 419
Self-citationMelissaridou, S., Wiechec, E., Magan, M., Jain, M. V., Chung, M. K., Farnebo, L., & Roberg, K. (2019) · Cancer Cell International · doi:10.1186/s12935-019-0733-1 · Cited by 262
Proteoglycans remodeling in cancer: Underlying molecular mechanisms
Theocharis, A. D., & Karamanos, N. K. (2019) · Matrix Biology · doi:10.1016/j.matbio.2017.10.008 · Cited by 203
Proceedings of the 16th Annual UT-KBRIN Bioinformatics Summit 2016: bioinformatics
Rouchka, E. C., Chariker, J. H., Tieri, D. A., Park, J. W., Rajurkar, S. D., Singh, V., Verma, N. K., Cui, Y., FARMAN, M. L., Condon, B. J., et al. (2017) · BMC Bioinformatics · doi:10.1186/s12859-017-1781-y · Cited by 112
Metadata
- Authors
- Li, C., Singh, B., Graves-Deal, R., Ma, H., Starchenko, A., Fry, W. H., Lu, Y., Wang, Y., Bogatcheva, G., Khan, M. P., Milne, G. L., Zhao, S., Ayers, G. D., Li, N., Hu, H., Washington, M. K., Yeatman, T. J., McDonald, O. G., Liu, Q., & Coffey, R. J.
- Affiliations
- Xiamen University (CN)
- Vanderbilt University (US)
- Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232;
- Whitehead Institute for Biomedical Research (US)
- Emory University (US)
- Vanderbilt University Medical Center (US)
- Peking Union Medical College Hospital (CN)
- Gibbs Cancer Center & Research Institute, Spartanburg, SC 29303;
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2017-03-20
- Volume
- 114
- Issue
- 14
- Pages
- E2852-E2861
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC5389279
- OpenAlex
- W2597422592
- Cited by
- 47
- References
- 63
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 7 · 2023: 3 · 2022: 3 · 2021: 7 · 2020: 10 · 2019: 6 · 2018: 4 · 2017: 5
- FWCI
- 3.01
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- HHS | NIH | National Cancer Institute (RO1 CA 46413, P50 95103)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Keywords
- cetuximab resistance, colorectal cancer, 3D cell culture, versican, 15-hydroxyprostaglandin dehydrogenase, prognostic factors, xenografts, disease-associated genes, EGFR inhibitors
- MeSH terms
- Cetuximab, Antineoplastic Agents, Immunological, Receptor, Transforming Growth Factor-beta Type II, Crizotinib, Animals, Humans, Hydroxyprostaglandin Dehydrogenases, Phosphorylation, Pyrazoles, Pyridines, Colorectal Neoplasms, Gene Expression Regulation, Neoplastic, Protein Serine-Threonine Kinases, Receptors, Transforming Growth Factor beta, Cell Culture Techniques, Drug Resistance, Neoplasm, Xenograft Model Antitumor Assays, Cell Line, Tumor, Tissue Array Analysis, Proto-Oncogene Proteins c-akt, Mice, Versicans
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Three-dimensional culture system identifies a new mode of cetuximab resistance and disease-relevant genes in colorectal cancer. https://app.cochat.ai/papers/10.1073/pnas.1618297114
- The paper
- Li, C., Singh, B., Graves-Deal, R., Ma, H., Starchenko, A., Fry, W. H., Lu, Y., Wang, Y., Bogatcheva, G., Khan, M. P., Milne, G. L., Zhao, S., Ayers, G. D., Li, N., Hu, H., Washington, M. K., Yeatman, T. J., McDonald, O. G., Liu, Q., & Coffey, R. J. (2017). Three-dimensional culture system identifies a new mode of cetuximab resistance and disease-relevant genes in colorectal cancer. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.1618297114
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.